Skip to main content
Premium Trial:

Request an Annual Quote

Clarient to Offer Qiagen's Therascreen KRAS Assay as CDx for Erbitux

NEW YORK (GenomeWeb News) – Qiagen today said that GE company Clarient will offer its therascreen KRAS RGQ PCR kit as a companion diagnostic.

Clarient will offer the test to help guide the use of Erbitux (cetuximab) for treating patients with metastatic colorectal cancer. Clarient chose the therascreen KRAS assay and Qiagen's Rotor-Gene Q molecular diagnostic platform after the US Food and Drug Administration approved the test in July, Qiagen said.

Clarient provides cancer laboratory testing services in the US.

The therascreen KRAS assay detects KRAS gene mutations and is used to help physicians predict which patients will likely respond to EGFR inhibitors, a class of drugs that includes Erbitux. Qiagen, which last night announced that its fourth-quarter revenues rose 4 percent, said that studies indicate that the US healthcare system could save more than $600 million annually by determining KRAS status in colorectal cancer patients and eliminating the unnecessary use of medicines.

Erbitux is marketed in the US by Bristol-Myers Squibb along with Eli Lily and its Imclone Systems unit. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

"We believe precision medicine is the new direction in diagnosing and treating cancer and Clarient uses state-of-the-art diagnostic technologies like the therascreen KRAS test to bring clarity and precision to physicians to assist them in making better treatment decisions for their patients," Carrie Eglinton Manner, CEO of Clarient, said in a statement. "Clarient’s comprehensive offering and fast turnaround time coupled with our experience with the therascreen KRAS test permits us to provide a higher level of performance."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.